WORCESTER, Mass., July 22, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that the Company held a meeting with the Veterinary Drugs Directorate (VDD) of Health Canada on July 14th in Ottawa, Canada. The meeting was a Pre-New Drug Submission (NDS) meeting for the purpose of outlining the Company’s proposed development plan for the veterinary application of Generex Oral-lyn, the Company’s proprietary oral insulin spray product, with a view to proceeding with the filing of an NDS. As a result of this meeting, the Company plans to prepare an IND package for submission to the VDD before the end of this year.
